MeSH term
Frequency | Condition_Probility | Analysis of Variance | 9 | 0.0 |
Animals | 33 | 0.0 |
Blotting, Western | 2 | 0.0 |
Catechol O-Methyltransferase/*genetics | 83 | 86.0 |
Comparative Study | 42 | 0.0 |
DNA Primers | 8 | 0.0 |
Gene Expression Regulation, Enzymologic/*physiology | 2 | 2.0 |
Genotype | 85 | 0.0 |
Humans | 294 | 0.0 |
Methylation | 11 | 1.0 |
Mice | 6 | 0.0 |
Polymorphism, Single Nucleotide | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Sex Factors | 11 | 0.0 |
*Variation (Genetics) | 5 | 0.0 |
Adult | 111 | 0.0 |
Alleles | 43 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
DNA Mutational Analysis | 6 | 0.0 |
Female | 167 | 0.0 |
Gene Frequency | 25 | 0.0 |
Haplotypes | 8 | 0.0 |
Male | 137 | 0.0 |
Middle Aged | 96 | 0.0 |
Minisatellite Repeats/genetics | 2 | 4.0 |
Monoamine Oxidase/*genetics | 10 | 14.0 |
Polymorphism, Genetic | 26 | 0.0 |
Polymorphism, Restriction Fragment Length | 10 | 0.0 |
Promoter Regions (Genetics)/genetics | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 140 | 0.0 |
Schizophrenia/enzymology/*genetics | 6 | 27.0 |
Disease Progression | 3 | 0.0 |
English Abstract | 14 | 0.0 |
Membrane Glycoproteins/*genetics | 6 | 1.0 |
Membrane Transport Proteins/*genetics | 2 | 3.0 |
Polymorphism, Genetic/*genetics | 19 | 1.0 |
Case-Control Studies | 24 | 0.0 |
Catechol O-Methyltransferase/*genetics/metabolism | 9 | 100.0 |
Estrogens/metabolism | 4 | 5.0 |
Risk Factors | 24 | 0.0 |
Aged | 57 | 0.0 |
Prognosis | 2 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Cohort Studies | 4 | 0.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Genetic Predisposition to Disease | 22 | 0.0 |
Odds Ratio | 7 | 0.0 |
*Polymorphism, Genetic | 36 | 0.0 |
Prospective Studies | 2 | 0.0 |
Questionnaires | 6 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 61 | 0.0 |
Risk Assessment | 3 | 0.0 |
United States/epidemiology | 3 | 0.0 |
Receptor, Serotonin, 5-HT2A | 4 | 10.0 |
Receptors, Dopamine D2/*genetics | 5 | 1.0 |
Receptors, Serotonin/*genetics | 2 | 2.0 |
Treatment Outcome | 4 | 0.0 |
Catechol O-Methyltransferase/genetics | 16 | 53.0 |
*Genetic Predisposition to Disease | 8 | 0.0 |
*Chromosomes, Human, Pair 22 | 7 | 3.0 |
Genetic Markers | 6 | 0.0 |
Genetic Predisposition to Disease/genetics | 6 | 1.0 |
Linkage Disequilibrium | 9 | 1.0 |
Pregnancy | 11 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Cross-Over Studies | 8 | 1.0 |
Double-Blind Method | 16 | 0.0 |
Drug Therapy, Combination | 7 | 0.0 |
Levodopa/administration & dosage/*therapeutic use | 2 | 100.0 |
Parkinson Disease/*drug therapy | 17 | 48.0 |
Enzyme Inhibitors/therapeutic use | 2 | 2.0 |
Antiparkinson Agents/adverse effects/*therapeutic use | 2 | 100.0 |
Catechols/adverse effects/*therapeutic use | 3 | 100.0 |
Chi-Square Distribution | 5 | 0.0 |
Antiparkinson Agents/*therapeutic use | 5 | 71.0 |
Randomized Controlled Trials | 2 | 0.0 |
Carrier Proteins/genetics | 6 | 1.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
*Membrane Transport Proteins | 10 | 1.0 |
Minisatellite Repeats | 3 | 2.0 |
Monoamine Oxidase/metabolism | 6 | 31.0 |
*Nerve Tissue Proteins | 13 | 2.0 |
Phenotype | 6 | 0.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
Receptors, Dopamine D2/genetics | 7 | 14.0 |
Adolescent | 27 | 0.0 |
Obsessive-Compulsive Disorder/enzymology/*genetics | 2 | 100.0 |
Sex Characteristics | 2 | 0.0 |
Reference Values | 13 | 0.0 |
Catechol O-Methyltransferase/*antagonists & inhibitors/metabolism | 5 | 83.0 |
In Vitro | 5 | 0.0 |
Liver/drug effects/enzymology | 2 | 3.0 |
Rats | 15 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Benzophenones/*pharmacology | 3 | 100.0 |
Dopamine/metabolism | 7 | 5.0 |
Enzyme Inhibitors/*pharmacology | 9 | 1.0 |
Tomography, Emission-Computed | 5 | 4.0 |
Carrier Proteins/*genetics | 6 | 0.0 |
Comorbidity | 2 | 0.0 |
Tryptophan Hydroxylase/*genetics | 2 | 22.0 |
*Cognition | 2 | 4.0 |
Neuropsychological Tests | 3 | 1.0 |
Catechol O-Methyltransferase/*metabolism | 18 | 90.0 |
Catecholamines/*metabolism | 5 | 9.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Kinetics | 11 | 0.0 |
Norepinephrine/metabolism | 3 | 6.0 |
Solubility | 3 | 0.0 |
Age of Onset | 3 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
Antiparkinson Agents/*administration & dosage | 2 | 66.0 |
Dose-Response Relationship, Drug | 19 | 0.0 |
Levodopa/*administration & dosage | 2 | 66.0 |
Retrospective Studies | 3 | 0.0 |
Japan/ethnology | 2 | 2.0 |
Polymerase Chain Reaction | 20 | 0.0 |
Benzophenones/pharmacology | 5 | 83.0 |
Catechol O-Methyltransferase/*antagonists & inhibitors | 26 | 92.0 |
*DNA Damage | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Estrogens, Catechol/*metabolism | 4 | 50.0 |
Oxidative Stress/physiology | 2 | 2.0 |
Heterozygote | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
S-Adenosylmethionine/metabolism | 3 | 15.0 |
Catechol O-Methyltransferase/genetics/*metabolism | 3 | 100.0 |
Cloning, Molecular | 7 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Mass Fragmentography | 2 | 0.0 |
Child | 14 | 0.0 |
Cognition/*physiology | 4 | 5.0 |
Methionine/genetics | 7 | 14.0 |
Valine/genetics | 7 | 10.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
South Africa/epidemiology | 2 | 3.0 |
Chromosomes, Human, Pair 22/*genetics | 3 | 3.0 |
Hospitalization | 3 | 2.0 |
Dopamine/*genetics | 2 | 15.0 |
Linkage (Genetics) | 5 | 0.0 |
Pedigree | 9 | 0.0 |
Psychiatric Status Rating Scales | 4 | 1.0 |
Serotonin/genetics | 2 | 25.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Isoenzymes/genetics | 4 | 1.0 |
Korea | 3 | 1.0 |
Neoplasms, Hormone-Dependent/enzymology/genetics | 2 | 100.0 |
Genetics, Population | 3 | 0.0 |
South Africa | 2 | 1.0 |
Bipolar Disorder/*genetics | 4 | 3.0 |
Receptors, Serotonin/genetics | 3 | 15.0 |
Area Under Curve | 6 | 1.0 |
Catechol O-Methyltransferase/*antagonists & inhibitors/blood | 4 | 80.0 |
Drug Interactions | 9 | 0.0 |
Enzyme Inhibitors/adverse effects/pharmacokinetics/*pharmacology | 3 | 75.0 |
Amino Acid Sequence | 4 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
*Family Health | 3 | 5.0 |
Israel | 3 | 1.0 |
Brain Chemistry/genetics | 2 | 4.0 |
*Membrane Glycoproteins | 5 | 0.0 |
Tryptophan Hydroxylase/genetics | 2 | 14.0 |
China | 2 | 0.0 |
Exploratory Behavior | 2 | 22.0 |
Personality/*genetics | 2 | 6.0 |
Reward | 2 | 5.0 |
Methyltransferases/genetics | 2 | 11.0 |
Pilot Projects | 2 | 0.0 |
Receptor, Serotonin, 5-HT2C | 2 | 10.0 |
Schizophrenic Psychology | 2 | 5.0 |
*Suicide, Attempted | 2 | 40.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 4 | 3.0 |
*Alleles | 3 | 0.0 |
Parkinson Disease/*genetics | 2 | 2.0 |
Gene Expression/*genetics | 3 | 2.0 |
Serotonin/*genetics | 2 | 22.0 |
Parkinson Disease/*drug therapy/*genetics | 2 | 100.0 |
Glutathione Transferase/genetics | 4 | 1.0 |
Confidence Intervals | 3 | 0.0 |
Levodopa/*therapeutic use | 3 | 16.0 |
Catechols/*therapeutic use | 2 | 100.0 |
Glutathione Transferase/*genetics | 3 | 0.0 |
Family Health | 3 | 0.0 |
Blood Platelets/*enzymology | 5 | 6.0 |
Catechol O-Methyltransferase/*blood | 26 | 92.0 |
Erythrocytes/*enzymology | 27 | 5.0 |
Monoamine Oxidase/*blood | 8 | 25.0 |
Parkinson Disease/*complications/drug therapy | 2 | 100.0 |
Base Sequence | 10 | 0.0 |
Dopamine/*metabolism | 4 | 3.0 |
Dopamine beta-Hydroxylase/genetics | 3 | 11.0 |
Monoamine Oxidase/genetics | 6 | 27.0 |
Cytochrome P-450 CYP1A1/genetics | 4 | 4.0 |
Epidemiology, Molecular | 3 | 3.0 |
Estrogens/biosynthesis/*metabolism | 2 | 50.0 |
Superoxide Dismutase/genetics | 2 | 2.0 |
Chromatography, High Pressure Liquid | 9 | 0.0 |
Cytosol/enzymology | 2 | 1.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Methylation/drug effects | 2 | 14.0 |
Catechol O-Methyltransferase/metabolism | 6 | 50.0 |
Neuregulin-1/genetics | 2 | 28.0 |
Child, Preschool | 5 | 0.0 |
Ireland/epidemiology | 3 | 8.0 |
Catechol O-Methyltransferase/*antagonists & inhibitors/*genetics | 2 | 100.0 |
*Linkage (Genetics) | 3 | 0.0 |
Receptors, Dopamine D1/genetics | 2 | 33.0 |
Turkey | 2 | 1.0 |
Catecholamines/metabolism | 6 | 13.0 |
Levodopa/pharmacokinetics | 2 | 100.0 |
Cell Line, Tumor | 2 | 0.0 |
Malondialdehyde/blood | 2 | 3.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Catechol O-Methyltransferase/blood | 3 | 60.0 |
Erythrocytes/drug effects/enzymology | 3 | 10.0 |
Tyrosine/analogs & derivatives/blood | 2 | 66.0 |
Catalysis | 3 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Incidence | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 5 | 0.0 |
Catechol O-Methyltransferase/*genetics/physiology | 2 | 100.0 |
Finland/epidemiology | 2 | 1.0 |
Brain/enzymology | 3 | 1.0 |
Nuclear Family | 3 | 1.0 |
Risk | 5 | 0.0 |
Exercise/*physiology | 3 | 0.0 |
Linear Models | 2 | 0.0 |
Europe/ethnology | 2 | 2.0 |
Gene Frequency/genetics | 5 | 1.0 |
England | 2 | 1.0 |
Benzophenones/pharmacology/*therapeutic use | 2 | 100.0 |
Catechols/pharmacology/*therapeutic use | 2 | 100.0 |
Body Mass Index | 2 | 0.0 |
Postmenopause | 3 | 1.0 |
Premenopause | 4 | 4.0 |
Drug Combinations | 5 | 0.0 |
Catechols/therapeutic use | 2 | 50.0 |
Clinical Trials | 4 | 0.0 |
Levodopa/metabolism | 3 | 23.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 4 | 16.0 |
Steroid 17-alpha-Hydroxylase/genetics | 4 | 14.0 |
Apolipoproteins E/*genetics | 2 | 0.0 |
Microdialysis | 2 | 7.0 |
Aromatase/genetics | 3 | 21.0 |
Levodopa/*pharmacokinetics | 2 | 66.0 |
Bipolar Disorder/enzymology/epidemiology/*genetics | 2 | 100.0 |
Haplotypes/genetics | 2 | 0.0 |
Genetic Screening | 5 | 0.0 |
*Sex Characteristics | 2 | 1.0 |
Administration, Oral | 6 | 0.0 |
Benzophenones/*pharmacokinetics/*pharmacology | 2 | 100.0 |
Biological Availability | 3 | 1.0 |
Erythrocytes/enzymology | 15 | 3.0 |
Infusions, Intravenous | 2 | 0.0 |
Catechol O-Methyltransferase/*biosynthesis | 2 | 100.0 |
Hamsters | 3 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Codon | 2 | 0.0 |
Antiparkinson Agents/*administration & dosage/adverse effects | 2 | 100.0 |
Enzyme Inhibitors/*administration & dosage/adverse effects | 2 | 66.0 |
Catechols/*pharmacology | 4 | 33.0 |
Psychotic Disorders/*genetics/psychology | 2 | 50.0 |
Schizophrenia/*genetics | 7 | 3.0 |
*Schizophrenic Psychology | 2 | 3.0 |
*Menopause | 2 | 3.0 |
Sweden | 3 | 1.0 |
Dopamine/physiology | 3 | 5.0 |
Monoamine Oxidase Inhibitors/therapeutic use | 2 | 100.0 |
Radioligand Assay | 2 | 0.0 |
Selegiline/therapeutic use | 3 | 75.0 |
Antipsychotic Agents/*therapeutic use | 2 | 6.0 |
Schizophrenia/*drug therapy/*genetics | 2 | 15.0 |
Breast Neoplasms/etiology/*genetics | 2 | 6.0 |
Catechol O-Methyltransferase/antagonists & inhibitors | 2 | 50.0 |
Delayed-Action Preparations | 2 | 1.0 |
Benzophenones/adverse effects/pharmacokinetics/*pharmacology | 2 | 100.0 |
Bipolar Disorder/*enzymology/genetics | 2 | 100.0 |
Codon/genetics | 2 | 0.0 |
Disease Susceptibility | 4 | 0.0 |
Enzyme Inhibitors/pharmacology/*therapeutic use | 2 | 12.0 |
Levodopa/*pharmacokinetics/therapeutic use | 2 | 100.0 |
*Tea | 2 | 9.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Half-Life | 7 | 1.0 |
Time Factors | 10 | 0.0 |
Temperature | 2 | 0.0 |
*Aggression | 2 | 12.0 |
Infant | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Homovanillic Acid/blood | 2 | 28.0 |
Random Allocation | 3 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Biotransformation | 2 | 0.0 |
Levodopa/pharmacology | 2 | 7.0 |
Monoamine Oxidase Inhibitors/*therapeutic use | 3 | 37.0 |
Drug Administration Schedule | 2 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Catechol O-Methyltransferase/blood/*metabolism | 2 | 100.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Monoamine Oxidase/*metabolism | 6 | 24.0 |
*Chromosome Mapping | 3 | 0.0 |
Cricetulus | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Liver/*enzymology | 3 | 0.0 |
3,4-Dihydroxyphenylacetic Acid/metabolism | 2 | 7.0 |
Homovanillic Acid/metabolism | 3 | 18.0 |
Blotting, Northern | 2 | 0.0 |
Cell Line | 5 | 0.0 |
Organ Specificity | 2 | 0.0 |
Breast Neoplasms/*enzymology/epidemiology/*genetics | 2 | 50.0 |
Blood Pressure/drug effects | 3 | 0.0 |
DNA/analysis | 2 | 0.0 |
Prefrontal Cortex/*enzymology | 2 | 66.0 |
Parkinson Disease/drug therapy/*enzymology | 2 | 50.0 |
Tyrosine 3-Monooxygenase/*physiology | 2 | 33.0 |
Epinephrine/metabolism | 2 | 13.0 |
Kidney/metabolism | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Placenta/*enzymology | 3 | 3.0 |
Biological Markers/blood/urine | 2 | 4.0 |
Japan | 2 | 0.0 |
Korea/epidemiology | 2 | 3.0 |
Liver/enzymology | 2 | 0.0 |
Swine | 2 | 0.0 |
Aromatic-L-Amino-Acid Decarboxylases/*metabolism | 2 | 33.0 |
Norepinephrine/*metabolism | 4 | 11.0 |
Schizophrenia/*enzymology/genetics | 2 | 25.0 |
Substrate Specificity | 4 | 0.0 |
*Cytochrome P-450 CYP1A1 | 2 | 50.0 |
Chronic Disease | 3 | 0.0 |
Catechol O-Methyltransferase/physiology | 2 | 100.0 |
Norepinephrine/*blood | 2 | 3.0 |
Levodopa/adverse effects/*therapeutic use | 2 | 100.0 |
Bipolar Disorder/enzymology | 2 | 25.0 |
Catechol O-Methyltransferase/blood/*genetics | 2 | 100.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Down Syndrome/*enzymology | 2 | 28.0 |
Tritium | 2 | 0.0 |
Tritium/diagnostic use | 2 | 1.0 |
Catechol O-Methyltransferase/*blood/genetics | 6 | 85.0 |
Gene Expression Regulation | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
Models, Genetic | 2 | 0.0 |
Age Factors | 3 | 0.0 |
Chromatography, Thin Layer | 2 | 1.0 |
*Pregnancy | 2 | 1.0 |
Dopamine beta-Hydroxylase/*blood | 6 | 4.0 |
Bipolar Disorder/enzymology/psychology | 2 | 100.0 |
Depressive Disorder/*enzymology/psychology | 2 | 50.0 |
Neuropsychological Tests/statistics & numerical data | 2 | 11.0 |
Blood Platelets/enzymology | 4 | 9.0 |
Catechol O-Methyltransferase/antagonists & inhibitors/*blood | 4 | 100.0 |
Chlorpromazine/pharmacology | 2 | 7.0 |
Lithium/pharmacology | 2 | 10.0 |
Magnesium/pharmacology | 2 | 1.0 |
Schizophrenia/*enzymology | 3 | 27.0 |
Breast Neoplasms/enzymology/*genetics | 2 | 7.0 |
Cells, Cultured | 4 | 0.0 |
Fibroblasts/*enzymology | 2 | 5.0 |
Fibroblasts/enzymology | 2 | 1.0 |
Schizophrenia, Paranoid/enzymology | 2 | 50.0 |
Bipolar Disorder/*enzymology | 2 | 50.0 |
Lithium/therapeutic use | 2 | 16.0 |
Membrane Transport Proteins/genetics | 2 | 6.0 |
